

**Title:** In reply.

Response to Letter to the Editor ‘Predictive Value of NT-proBNP in Patients with Acute Myocardial Infarction’; Regarding Article ‘Trimethylamine N-oxide and Risk Stratification after Acute Myocardial Infarction’

**Authors:** Toru Suzuki<sup>1,2</sup>, Liam M Heaney<sup>1</sup>, Donald JL Jones<sup>1,3</sup>, Leong L Ng<sup>1</sup>

**Affiliations:**

<sup>1</sup> Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, United Kingdom

<sup>2</sup> Jichi Medical University, 3311-1 Yakushiji, Shimotsuke-shi, Tochigi-ken 329-0498, Japan

<sup>3</sup> Department of Cancer Studies, University of Leicester, RKCSB, Leicester, LE2 7LX, United Kingdom

**Address for correspondence:**

Prof Toru Suzuki, Department of Cardiovascular Sciences and NIHR Leicester Cardiovascular Biomedical Research Unit, Glenfield Hospital, Leicester, LE3 9QP, United Kingdom. Email: [ts263@le.ac.uk](mailto:ts263@le.ac.uk). Tel: (+44) 0116 204 4741

In our manuscript, trimethylamine N-oxide (TMAO), as the biomarker of focus, was analyzed retrospectively after previously understanding its prognostic ability in acute heart failure (1), and, we hypothesized that it might be prognostic for other acute cardiovascular conditions, namely acute myocardial infarction (MI). For this, we used a well-documented historical cohort that had been previously investigated for several biomarkers, including N-terminal pro B-type natriuretic peptide (NT-proBNP), and therefore would allow for comparison of the predictive ability of TMAO to the previously investigated/established biomarkers (e.g. Proenkephalin) (2). Previous analysis in this cohort has shown NT-proBNP to be a marker of adverse outcome when used alone (3) but not when combined with other contemporary markers (e.g. Proenkephalin) (2). The plasma concentrations of NT-proBNP were measured within 12-24 months of sample collection using an in-house assay that has shown strong correlation with the Roche Diagnostics assay ( $r=0.90$ ) (2).

In response to the present inquiry, additional analyses of the available NT-proBNP data over different time-points (i.e. admission and discharge) were performed. Circulating concentrations at admission were approximately 20% higher than at later time points [median (inter-quartile range) 1075 (324-2692) pmol/L vs 812 (259-2199) pmol/L, respectively]. To investigate the prognostic ability of NT-proBNP, we used fully-loaded Cox regression models including NT-proBNP, but excluding TMAO, which indicated that NT-proBNP concentrations at admission were not able to independently predict outcome at 6 months or 2 years ( $P>0.1$ ), with discharge samples prognostic at 6 months ( $P\leq 0.048$ ) but not 2 years ( $P>0.1$ ). These results are consistent with a previous report using this cohort (2).

As described within the manuscript, the patients in our study were representative of a patient population treated with a prior more risk-averse approach to invasive revascularization procedures consistent with standard of care at the time. Statistical investigations were appropriately adjusted for the rates of revascularization. The mentioned

manuscript by Heeschen et al. (4) used patients originating from the PRISM study, which also showed similar rates of revascularization at 30 days (26% versus 21%, respectively) (5). However, our cohort does reflect a much larger proportion of ST-elevated MI (47% versus 7%, respectively) but, as we did with revascularization, we adjusted our analyses by including STEMI class in the regression statistics.

In conclusion, plasma NT-proBNP concentrations in our cohort of acute MI patients were not able to independently predict outcome at 6 months or 2 years when included in a fully-loaded Cox regression model including the biomarker of focus, TMAO. Exclusion of TMAO allowed prognostic prediction of adverse outcome at 6 months, but only in samples collected at discharge. Alternative demographics were observed in comparison to a previous cohort and did not follow similar prognostic qualities to previous reports, although the shortest-term prediction we investigated was at 6 months, compared to previous investigation at 30 days (4). Despite discrepancies among cohorts, BNP measurements have been collectively shown to predict outcome in acute coronary syndrome investigations and remain an important aspect of clinical practice.

## References

1. Suzuki T, Heaney LM, Bhandari SS, Jones DJ, Ng LL. Trimethylamine N-oxide and prognosis in acute heart failure. *Heart* 2016;102:841-8.
2. Ng LL, Sandhu JK, Narayan H, Quinn PA, Squire IB, Davies JE, et al. Proenkephalin and prognosis after acute myocardial infarction. *J Am Coll Cardiol* 2014;63:280-9.
3. Squire I, Quinn P, Narayan H, Khan S, Dhillon O, Ng K, Kelly D, Davies J, Ng L. Identification of potential outcome benefit from ACE inhibition after acute coronary syndrome: a biomarker approach using N-terminal proBNP. *Heart* 2010;96:831-7.
4. Heeschen C, Hamm CW, Mitrovic V, Lantelme NH, White HD. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. *Circulation* 2004;110:3206-12.
5. Platelet receptor inhibition in ischemic syndrome management (PRISM) study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. *N Engl J Med* 1998;338:1498-505.